284 related articles for article (PubMed ID: 32170378)
21. Highly proliferative and functional PD-1
Batorov EV; Aristova TA; Pronkina NV; Sergeevicheva VV; Sizikova SA; Ushakova GY; Shevela EY; Ostanin AA; Chernykh ER
Int Immunopharmacol; 2021 Nov; 100():108093. PubMed ID: 34474273
[TBL] [Abstract][Full Text] [Related]
22. Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma.
Li Z; Li N; Li F; Zhou Z; Sang J; Chen Y; Han Q; Lv Y; Liu Z
Medicine (Baltimore); 2016 Dec; 95(52):e5749. PubMed ID: 28033288
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma.
Zhang L; Du H; Xiao TW; Liu JZ; Liu GZ; Wang JX; Li GY; Wang LX
Biomed Pharmacother; 2015 Oct; 75():83-7. PubMed ID: 26463635
[TBL] [Abstract][Full Text] [Related]
24. According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1
Moreno-Cubero E; Subirá D; Sanz-de-Villalobos E; Parra-Cid T; Madejón A; Miquel J; Olveira A; González-Praetorius A; García-Samaniego J; Larrubia JR
J Virol; 2018 Jan; 92(2):. PubMed ID: 29093082
[TBL] [Abstract][Full Text] [Related]
25. Early transient suppression of immune checkpoint proteins T-cell immunoglobulin mucin-3 and programmed cell death-1 in peripheral blood lymphocytes after blastocyst transfer is associated with successful implantation.
Zhang T; Zhu W; Zhao Y; Cheung WC; Liu Y; Chen X; Du Y; Leung KT; Chan YL; Wang CC; Laird S; Li TC
Fertil Steril; 2020 Aug; 114(2):426-435. PubMed ID: 32199622
[TBL] [Abstract][Full Text] [Related]
26. Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.
Datar I; Sanmamed MF; Wang J; Henick BS; Choi J; Badri T; Dong W; Mani N; Toki M; Mejías LD; Lozano MD; Perez-Gracia JL; Velcheti V; Hellmann MD; Gainor JF; McEachern K; Jenkins D; Syrigos K; Politi K; Gettinger S; Rimm DL; Herbst RS; Melero I; Chen L; Schalper KA
Clin Cancer Res; 2019 Aug; 25(15):4663-4673. PubMed ID: 31053602
[TBL] [Abstract][Full Text] [Related]
27. Expression analysis of PD-1 and Tim-3 immune checkpoint receptors in patients with vitiligo; positive association with disease activity.
Rahimi A; Hossein-Nataj H; Hajheydari Z; Aryanian Z; Shayannia A; Ajami A; Asgarian-Omran H
Exp Dermatol; 2019 Jun; 28(6):674-681. PubMed ID: 31046170
[TBL] [Abstract][Full Text] [Related]
28. Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1
Ye L; Zhang Q; Cheng Y; Chen X; Wang G; Shi M; Zhang T; Cao Y; Pan H; Zhang L; Wang G; Deng Y; Yang Y; Chen G
J Immunother Cancer; 2018 Dec; 6(1):145. PubMed ID: 30526680
[TBL] [Abstract][Full Text] [Related]
29. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.
Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V
Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124
[TBL] [Abstract][Full Text] [Related]
30. An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer.
Takano S; Saito H; Ikeguchi M
Surg Today; 2016 Nov; 46(11):1341-7. PubMed ID: 26801344
[TBL] [Abstract][Full Text] [Related]
31. The prognostic and clinicopathological significance of Tim-3 and PD-1 expression in the prognosis of upper urinary tract urothelial carcinoma.
Chen H; Wang M; Weng T; Wei Y; Liu C; Yang L; Ren K; Tang Y; Tang Z; Gou X
Urol Oncol; 2021 Nov; 39(11):743-753. PubMed ID: 34330653
[TBL] [Abstract][Full Text] [Related]
32. Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors.
Kroy DC; Ciuffreda D; Cooperrider JH; Tomlinson M; Hauck GD; Aneja J; Berger C; Wolski D; Carrington M; Wherry EJ; Chung RT; Tanabe KK; Elias N; Freeman GJ; de Kruyff RH; Misdraji J; Kim AY; Lauer GM
Gastroenterology; 2014 Feb; 146(2):550-61. PubMed ID: 24148617
[TBL] [Abstract][Full Text] [Related]
33. T-Cell surface CCR5 density is not correlated with hepatitis severity in hepatitis C virus/HIV-coinfected individuals: implications for the therapeutic use of CCR5 antagonists.
Vincent T; Portales P; Baillat V; de Boever CM; Le Moing V; Vidal M; Ducos J; Clot J; Reynes J; Corbeau P
J Acquir Immune Defic Syndr; 2005 Mar; 38(3):305-9. PubMed ID: 15735449
[TBL] [Abstract][Full Text] [Related]
34. Peripheral immune characteristics of hepatitis B virus-related hepatocellular carcinoma.
Sun R; Li J; Lin X; Yang Y; Liu B; Lan T; Xiao S; Deng A; Yin Z; Xu Y; Xiang Z; Wu B
Front Immunol; 2023; 14():1079495. PubMed ID: 37077908
[TBL] [Abstract][Full Text] [Related]
35. Peripheral loss of CD8(+) CD161(++) TCRVα7·2(+) mucosal-associated invariant T cells in chronic hepatitis C virus-infected patients.
Barathan M; Mohamed R; Vadivelu J; Chang LY; Saeidi A; Yong YK; Ravishankar Ram M; Gopal K; Velu V; Larsson M; Shankar EM
Eur J Clin Invest; 2016 Feb; 46(2):170-80. PubMed ID: 26681320
[TBL] [Abstract][Full Text] [Related]
36. Tumor antigen-specific CD8
Lu X; Yang L; Yao D; Wu X; Li J; Liu X; Deng L; Huang C; Wang Y; Li D; Liu J
Cell Immunol; 2017 Mar; 313():43-51. PubMed ID: 28110884
[TBL] [Abstract][Full Text] [Related]
37. Peripheral PD-1
Romani S; Stafford K; Nelson A; Bagchi S; Kottilil S; Poonia B
Front Immunol; 2019; 10():1470. PubMed ID: 31316516
[TBL] [Abstract][Full Text] [Related]
38. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint.
Chen J; Ji T; Zhao J; Li G; Zhang J; Jin R; Liu J; Liu X; Liang X; Huang D; Xie A; Lin H; Cang Y; Cai X
Oncotarget; 2016 Jul; 7(27):41274-41284. PubMed ID: 27129180
[TBL] [Abstract][Full Text] [Related]
40. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
